What Was Approved?
On August 26, 2026, the U.S. Food and Drug Administration approved Rasonque (daraxonrasib) for the treatment of metastatic pancreatic cancer.
Rasonque is a targeted therapy designed to inhibit certain forms of the RAS protein, which can play an important role in driving pancreatic cancer growth.
What Type of Pancreatic Cancer Is Involved?
The FDA announcement describes the approval as a new treatment option for advanced pancreatic adenocarcinoma.
Pancreatic adenocarcinoma is the most common form of pancreatic cancer and develops from cells that line the ducts of the pancreas.
How Does Rasonque Work?
Rasonque is a RAS inhibitor.
RAS proteins help regulate cell growth. In many cancers, abnormal RAS signaling can contribute to uncontrolled tumor growth.
Rasonque is designed to target multiple forms of RAS involved in pancreatic cancer.
How Is Rasonque Taken?
According to the FDA approval announcement, Rasonque is an oral tablet taken once daily.
Patients should follow the exact dosing and administration instructions provided in the FDA-approved prescribing information.
Why Is This Approval Important?
Metastatic pancreatic cancer remains one of the most difficult cancers to treat.
The approval of Rasonque introduces a new targeted treatment option for patients with advanced disease and represents a new approach focused on RAS signaling.
Is Rasonque Appropriate for Every Patient With Pancreatic Cancer?
No.
Treatment decisions depend on factors such as:
- Cancer type
- Stage of disease
- Tumor characteristics
- Previous treatments
- Overall health
- Other medications
Patients should discuss whether a targeted therapy is appropriate with their oncology team.
What Should Patients Know About Safety?
As with other cancer therapies, Rasonque may cause adverse effects and may require monitoring.
Patients should review the FDA-approved prescribing information and discuss:
- Possible side effects
- Drug interactions
- Laboratory monitoring
- Other medical conditions
- Pregnancy considerations
- Other cancer treatments
with their oncology team and pharmacist.
Bottom Line
Rasonque (daraxonrasib) is a newly approved targeted therapy for metastatic pancreatic cancer.
Its approval adds a new oral treatment option and introduces a RAS-targeted approach for a cancer that has historically been difficult to treat.
Sources
- U.S. Food and Drug Administration (FDA) — FDA Approves First in Class Targeted Therapy for Metastatic Pancreatic Cancer, August 26, 2026.
- U.S. Food and Drug Administration (FDA) — Novel Drug Approvals for 2026.